Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

Isabella Castellano, Elena Allia, Valeria Accortanzo, Anna Maria Vandone, Luigi Chiusa, Riccardo Arisio, Antonio Durando, Michela Donadio, Gianni Bussolati, Alan S. Coates, Giuseppe Viale, Anna Sapino

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P <0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P <0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P <0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.

Original languageEnglish
Pages (from-to)607-617
Number of pages11
JournalBreast Cancer Research and Treatment
Volume124
Issue number3
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Androgen Receptors
Estrogen Receptors
Breast Neoplasms
Recurrence
Survival
Proportional Hazards Models
Immunohistochemistry
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Androgen receptor
  • Breast cancer
  • Chemotherapy
  • Estrogen receptor
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. / Castellano, Isabella; Allia, Elena; Accortanzo, Valeria; Vandone, Anna Maria; Chiusa, Luigi; Arisio, Riccardo; Durando, Antonio; Donadio, Michela; Bussolati, Gianni; Coates, Alan S.; Viale, Giuseppe; Sapino, Anna.

In: Breast Cancer Research and Treatment, Vol. 124, No. 3, 12.2010, p. 607-617.

Research output: Contribution to journalArticle

Castellano, I, Allia, E, Accortanzo, V, Vandone, AM, Chiusa, L, Arisio, R, Durando, A, Donadio, M, Bussolati, G, Coates, AS, Viale, G & Sapino, A 2010, 'Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers', Breast Cancer Research and Treatment, vol. 124, no. 3, pp. 607-617. https://doi.org/10.1007/s10549-010-0761-y
Castellano, Isabella ; Allia, Elena ; Accortanzo, Valeria ; Vandone, Anna Maria ; Chiusa, Luigi ; Arisio, Riccardo ; Durando, Antonio ; Donadio, Michela ; Bussolati, Gianni ; Coates, Alan S. ; Viale, Giuseppe ; Sapino, Anna. / Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. In: Breast Cancer Research and Treatment. 2010 ; Vol. 124, No. 3. pp. 607-617.
@article{5caed88e5e7f48639fc91f20547d2e6f,
title = "Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers",
abstract = "The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9{\%}). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P <0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P <0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95{\%}CI 0.258-0.765) and DSS (P <0.001, HR 0.135, 95{\%}CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95{\%}CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95{\%} CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.",
keywords = "Androgen receptor, Breast cancer, Chemotherapy, Estrogen receptor, Prognosis",
author = "Isabella Castellano and Elena Allia and Valeria Accortanzo and Vandone, {Anna Maria} and Luigi Chiusa and Riccardo Arisio and Antonio Durando and Michela Donadio and Gianni Bussolati and Coates, {Alan S.} and Giuseppe Viale and Anna Sapino",
year = "2010",
month = "12",
doi = "10.1007/s10549-010-0761-y",
language = "English",
volume = "124",
pages = "607--617",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

AU - Castellano, Isabella

AU - Allia, Elena

AU - Accortanzo, Valeria

AU - Vandone, Anna Maria

AU - Chiusa, Luigi

AU - Arisio, Riccardo

AU - Durando, Antonio

AU - Donadio, Michela

AU - Bussolati, Gianni

AU - Coates, Alan S.

AU - Viale, Giuseppe

AU - Sapino, Anna

PY - 2010/12

Y1 - 2010/12

N2 - The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P <0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P <0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P <0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.

AB - The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P <0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P <0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P <0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.

KW - Androgen receptor

KW - Breast cancer

KW - Chemotherapy

KW - Estrogen receptor

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=78249249431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249249431&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-0761-y

DO - 10.1007/s10549-010-0761-y

M3 - Article

VL - 124

SP - 607

EP - 617

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -